Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNC 105

Drug Profile

BNC 105

Alternative Names: BNC 105P; BNC-105

Latest Information Update: 23 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iliad Chemicals
  • Developer Bionomics
  • Class Anisoles; Antineoplastics; Benzofurans; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Mesothelioma; Renal cell carcinoma
  • Phase I/II Ovarian cancer
  • Discontinued Chronic lymphocytic leukaemia; Colorectal cancer

Most Recent Events

  • 23 Feb 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in Australia (unspecified route)
  • 23 Feb 2023 Discontinued - Preclinical for Colorectal cancer in Australia (IV)
  • 17 Feb 2021 EmpathBio collaborates with Bionomics to explore a combination drug treatment for Post-traumatic stress disorder
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top